| Stimit–Dräger: investment, 202104 acquisition of majority share in Stimit AG by Drägerwerk AG & Co KGaA |
2021-04-01 |
| Cytosurge–Univ Tübingen: genome editing, 202103 collab cell line developm using FluidFM nano-injection for single cell CRISPR gene engineering |
2021-03-24 |
| Formycon–Leukocare: biopharmaceuticals, 202103– collab Master Service Agreem developm stable formulations for biosimilars/biologics of Formycon |
2021-03-24 |
| Indivumed–Live Wire Strategic Communications: public relations, 202103 service existent by Live Wire |
2021-03-18 |
| AgomAb Therapeutics–Boehringer: investment, 202103 financing round Series B totalling $74m incl existing + co-investor BIVF |
2021-03-10 |
| AgomAb Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications |
2021-03-10 |
| BellaSeno–Akampion: public relations, 202103 service existent by Akampion |
2021-03-10 |
| BellaSeno–Fraunhofer: implant production technology, 202103– collab developm automated resorbable implant production + QC with Fraunhofer IPT |
2021-03-10 |
| BellaSeno–Germany (govt): grant, 202103– KUM-innovativ grant totalling €1.4m tog with Fraunhofer IPT from BMBF |
2021-03-10 |
| Lophius–Mikrogen: investment, 202103 acquisition of assets + technologies incl takeover of entire team + lab in Regensburg by Mikrogen |
2021-03-08 |
| Atai Life Sciences–KCSA Strategic Communications: public relations, 202103 service existent KCSA is media contact |
2021-03-03 |
| Atai Life Sciences–SEVERAL: investment, 202103 financing round Series D $157m co-led by Apeiron + Thiel Capital |
2021-03-03 |
| ActiTrexx–SEVERAL: investment, 202103 financing round Series A €3.5m led by LBBW Venture Capital GmbH |
2021-03-02 |
| Kairos GmbH–Iqvia: investment, 202103 acquisition of Kairos GmbH by Iqvia |
2021-03-01 |
| InfanDx–Akampion: public relations, 202102 service existent by Akampion |
2021-02-04 |
| Genopis–Wacker: investment, 202102 acquisition of Genopis Inc for $39m in cash + milestones from Helixmith Co Ltd + Medivate Partners LLC |
2021-02-03 |
| Carisma Therapeutics–Cevec: cell line technology, 202102– license €na for use of CAP technology to produce adenovirus vectors for cancer cell therapy |
2021-02-02 |
| Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test |
2021-01-28 |
| GeneQuine–Brandenburg (govt): grant, 202101 grant €900k from investment bank of federal state Brandenburg |
2021-01-26 |
| GeneQuine–High-Tech Gründerfonds: investment, 202101 financing round Series A totalling €5.4m incl existing + co-investor HTGF |
2021-01-26 |
| GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA |
2021-01-26 |
| GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences |
2021-01-26 |
| GeneQuine–Samum: credit, 202101 convertible loans totalling €2.75m from Pacira BioSciences Inc + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Samum: investment, 202101 financing round Series A totalling €5.4m incl co-investor Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences |
2021-01-26 |
| i3 Membrane–High-Tech Gründerfonds: investment, 202101 financing round totalling 7-figure € sum inkl existing investor HTGF |
2021-01-25 |
| i3 Membrane–OTHER: investment, 202101 financing round totalling 7-figure € sum incl three private investors |
2021-01-25 |
| i3 Membrane–SEVERAL: investment, 202101 financing round 7-figure € sum from HTGF + three private investors |
2021-01-25 |
| Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx |
2021-01-21 |
| AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones |
2021-01-20 |
| Relief Therapeutics–MC Services: public relations, 202101 service existent by MC Services |
2021-01-20 |
| LignoPure–Hamburg (govt): investment, 202101 seed financing round totalling €2.2m incl investor Innovationsstarter Fonds Hamburg GmbH |
2021-01-18 |
| LignoPure–High-Tech Gründerfonds: investment, 202101 seed financing round totalling €2.2m incl investor HTGF |
2021-01-18 |
| LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG |
2021-01-18 |
| LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG |
2021-01-18 |
| Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors |
2021-01-13 |
| Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share |
2021-01-12 |
| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Labforward–2mag: investment, 202101 financing round Series B totalling >€5m incl new + co-investor 2mag |
2021-01-11 |
| Labforward–Peppermint: investment, 202101 financing round Series B totalling >€5m incl existing + co-investor Peppermint VenturePartners |
2021-01-11 |
| Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners |
2021-01-11 |
| Labforward–Tecan: investment, 202101 financing round Series B totalling >€5m incl €4m from new + lead investor Tecan resulting in 10% stake |
2021-01-11 |
| Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies |
2021-01-08 |
| AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck |
2021-01-07 |
| BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital |
2021-01-07 |
| Cellectis–Sirion Biotech: cell/gene therapy manufacturing technology, 202101– non-excl license €na to LentiBoost technology for CAR-T cell therapies |
2021-01-07 |
| Sterna Biologicals–SEVERAL: investment, 202101 financing round Series A 2nd closing €10m bringing total Series A to €22m |
2021-01-07 |
| Eleva–Zukunftsfonds Heilbronn: investment, 202101– up to €60m for development of CPV-101 |
2021-01-06 |
| Somatex Medical Technologies–Hologic: investment, 202101 acquisition $64m of Somatex by Hologic |
2021-01-04 |
| Biosun Biochemicals–BRAIN: investment, 202101 acquisition 100% €na by BRAIN AG |
2021-01-01 |
| MYR GmbH–Gilead Sciences: investment, 202012 acquisition €1.15b in cash + €300m milestones of MYR GmbH by Gilead Sciences Inc |
2020-12-10 |
| NBE Therapeutics–Boehringer: investment, 202012– acquisition up to €1.18b by Boehringer |
2020-12-10 |
| Resolve Biosciences–Alafi Capital: investment, 202012 financing round Series A totalling $24m incl co-investor Alafi Capital |
2020-12-10 |
| Resolve Biosciences–Bioscribe: public relations, 202012 service existent by Bioscribe |
2020-12-10 |
| Resolve Biosciences–High-Tech Gründerfonds: investment, 202012 financing round Series A totalling $24m incl co-investor HTGF |
2020-12-10 |
| Resolve Biosciences–MasterMind Advisory Services: investment, 202012 financing round Series A totalling $24m incl co-lead investor MasterMind |
2020-12-10 |
| Resolve Biosciences–PERSON: investment, 202012 financing round Series A totalling $24m incl co-investor John Shoffner |
2020-12-10 |
| Resolve Biosciences–PS Capital Management: investment, 202012 financing round Series A totalling $24m incl co-lead investor PS Capital |
2020-12-10 |
| Resolve Biosciences–SEVERAL: investment, 202012 financing round Series A $24m co-led by PS Capital Management + MasterMind Advisory Services |
2020-12-10 |
| Curexsys–Evotec: investment, 202012 seed financing round totalling €8.2m incl Evotec acquiring 37% equity stake |
2020-12-09 |
| Curexsys–Sartorius: investment, 202012 seed financing round totalling €8.2m incl Sartorius acquiring 21% equity stake |
2020-12-09 |
| Curexsys–SEVERAL: investment, 202012 seed financing round €8.2m led by Evotec + Sartorius |
2020-12-09 |
| Biomes NGS–GPS Ventures: investment, 202012 pre-series A investment €2m from GPS Ventures GmbH |
2020-12-07 |
| Boehringer–Proxygen: molecular glue degraders, 202012– collab + license agreem developm in combi with PROTACs against oncogenic targets |
2020-12-07 |
| Adrenomed–HBM: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor HBM Healthcare Investments |
2020-11-30 |
| Adrenomed–SEVERAL: investment, 202011 financing round Series E €22.2m co-led by Wellington Partners + HBM |
2020-11-30 |
| Adrenomed–Wellington Partners: investment, 202011 financing round Series E totalling €22.2m incl existing + co-lead investor Wellington Partners |
2020-11-30 |
| BioNTech–InstaDeep: AI-based drug discovery, 2019– collab initiated in 2019 |
2020-11-25 |
| BioNTech–InstaDeep: AI-based drug discovery, 202011– strategic collab incl joined AI Innovation Lab to develop immunotherapies |
2020-11-25 |
| Emergence Therapeutics–High-Tech Gründerfonds: investment, 202011 follow-on seed financing round incl lead investor HTGF |
2020-11-25 |
| Emergence Therapeutics–SEVERAL: investment, 202011 follow-on seed financing round led by HTGF |
2020-11-25 |
| Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund |
2020-11-25 |
| Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG |
2020-11-25 |
| Atai Life Sciences–SEVERAL: investment, 202011 financing round Series C $125m incl $32m converted debt co-led by Apeiron + Peter Thiel + Catalio |
2020-11-23 |
| m2p-labs–Danaher: investment, 202011 acquisition of m2p-biolabs by Beckman Coulter Life Sciences |
2020-11-12 |
| MorphoSys–Cherry Biolabs: Hemibody technology, 202011– license €na to apply Hemibody technology to six exclusive targets |
2020-11-11 |
| Catalym–Bavaria (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Wachstumsfonds Bayern |
2020-11-10 |
| Catalym–Germany (govt): investment, 202011 financing round Series B totalling €50m incl co-investor Coparion |
2020-11-10 |
| Catalym–Novartis: investment, 202011 financing round Series B totalling €50m incl co-investor Novartis Venture Fund |
2020-11-10 |
| Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III |
2020-11-10 |
| Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III |
2020-11-10 |
| Roche–Cevec: cell line technology, 202011– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies |
2020-11-10 |
| Vera Therapeutics–Merck (DE): investment, 202011 Merck reveices 10% equity in Vera Tx as part of license deal for atacicept |
2020-11-09 |
| Polaris Science (SG)–Nynomic: plant phenotyping, 202011– distribution in Singapore + Malaysia of LemnaTec solutions for phenotyping + seed testing |
2020-11-01 |
| TVM–Lilly: investment, 202010 final closing totalling $478m of fund TVM Life Science Innovation II incl investor Eli Lilly |
2020-10-27 |
| TVM–OCP Capital: investment banking, –202010 supply service OCP supports fund raising for $478m TMV LSI II fund |
2020-10-27 |
| TVM–SEVERAL: investment, 202010 final closing of $478m of fund TVM Life Science Innovation II incl Eli Lilly |
2020-10-27 |
| AskBio–Bayer: investment, 202010 acquisition by Bayer for $2b upfront plus $2b milestones |
2020-10-26 |
| Eternygen–SEVERAL: investment, 202010 financing round Series A2 1st closing €5m led by Evotec |
2020-10-26 |
| MD Biosciences–MLM Medical Labs: investment, 202010 acquisition of MD Biosciences Inc by MLM Medical Labs |
2020-10-26 |
| ChromoTek–Proteintech: investment, 202010 acquisition of ChromoTek by Proteintech Group |
2020-10-20 |
| Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners |
2020-10-19 |
| Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF |
2020-10-19 |
| Topas Therapeutics–EMBL: investment, 202010 financing round Series B totalling €22m incl existing + co-investor EMBL Ventures |
2020-10-19 |
| Topas Therapeutics–Epidarex Capital: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Epidarex Capital |
2020-10-19 |
| Topas Therapeutics–Evotec: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Evotec |
2020-10-19 |
| Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv |
2020-10-19 |
| Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors |
2020-10-19 |
| Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III |
2020-10-19 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] No Content Marketing 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
